Semaglutide is effective in type 2 diabetes and obesity with schizophrenia

被引：0
|
作者：
Kaoru Noda
Takehiro Kato
Nao Nomura
Mayu Sakai
Sodai Kubota
Tokuyuki Hirose
Yanyan Liu
Yoshihiro Takahashi
Ken Takao
Masami Mizuno
Takuo Hirota
Tetsuya Suwa
Yukio Horikawa
Daisuke Yabe
机构：
[1] Gifu University Graduate School of Medicine,Department of Diabetes, Endocrinology and Metabolism
[2] Gifu University Graduate School of Medicine,Department of Rheumatology and Clinical Immunology
[3] Kansai Electric Power Medical Research Institute,Yutaka Seino Distinguished Center for Diabetes Research
[4] Tokai National Higher Education and Research System,Center for Healthcare Information Technology
[5] Kobe University Graduate School of Medicine,Division of Molecular and Metabolic Medicine
来源：
Diabetology International | 2022年 / 13卷
关键词：
GLP-1 receptor agonist; Schizophrenia; Obesity; Type 2 diabetes; Bodyweight;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：693 / 697
页数：4
相关论文
共 50 条
  • [1] Semaglutide is effective in type 2 diabetes and obesity with schizophrenia
    Noda, Kaoru
    Kato, Takehiro
    Nomura, Nao
    Sakai, Mayu
    Kubota, Sodai
    Hirose, Tokuyuki
    Liu, Yanyan
    Takahashi, Yoshihiro
    Takao, Ken
    Mizuno, Masami
    Hirota, Takuo
    Suwa, Tetsuya
    Horikawa, Yukio
    Yabe, Daisuke
    DIABETOLOGY INTERNATIONAL, 2022, 13 (04) : 693 - 697
  • [2] Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes
    Cohen, Charlotte
    Cohen, Regis
    Sabouret, Pierre
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 380 - 382
  • [3] Semaglutide improves Heart Failure Symptoms in Obesity and Type 2 Diabetes
    Franke, Katharina
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2025, 150 (07) : 320 - 321
  • [4] Semaglutide and Type 2 diabetes
    Malbos, Damien
    ACTUALITES PHARMACEUTIQUES, 2021, 60 (608): : 5 - 5
  • [5] Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
    Jimenez, Beatriz Rodriguez
    Gomez, Pablo Rodriguez de Vera
    Lomas, Samuel Belmonte
    Diaz, angel Manuel Mesa
    Mateos, Irene Caballero
    Galan, Irene
    Portillo, Cristobal Morales
    Martinez-Brocca, Maria Asuncion
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [6] Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes Reply
    Bendapudi, Pavan K.
    Stefely, Jonathan A.
    Makar, Robert S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 383 - 384
  • [7] Oral semaglutide in type 2 diabetes
    Anderson, Sarah L.
    Beutel, Trevor R.
    Trujillo, Jennifer M.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (04)
  • [8] New practice in semaglutide on type-2 diabetes and obesity:clinical evidence and expectation
    Yalin Liu
    Xianghang Luo
    Frontiers of Medicine, 2022, 16 (01) : 17 - 24
  • [9] Tirzepatide versus Semaglutide 2.4 mg for People with Obesity or Overweight and Type 2 Diabetes
    Hankosky, Emily
    Brumm, Julia Fraseur
    Malik, Raleigh
    Niemeyer, Anthony
    Wang, Fangyu
    Zhang, Xiaotian Michelle
    He, Xuanyao
    OBESITY, 2023, 31 : 83 - 84
  • [10] Semaglutide and Psilocybin in a Mouse Model of Obesity, Steatotic Liver Disease and Type 2 Diabetes
    De Martin, Sara
    Colognesi, Martina
    Gabbia, Daniela
    Comai, Stefano
    Mattarei, Andrea
    Pasut, Gianfranco
    Centofanti, Lucia
    la Rosa, Stefano
    Finzi, Giovanna
    Folli, Franco
    Pappagallo, Marco
    Manfredi, Paolo
    OBESITY, 2024, 32 : 9 - 10
12345